240 related articles for article (PubMed ID: 32976029)
21. Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease.
Favre D; Mold J; Hunt PW; Kanwar B; Loke P; Seu L; Barbour JD; Lowe MM; Jayawardene A; Aweeka F; Huang Y; Douek DC; Brenchley JM; Martin JN; Hecht FM; Deeks SG; McCune JM
Sci Transl Med; 2010 May; 2(32):32ra36. PubMed ID: 20484731
[TBL] [Abstract][Full Text] [Related]
22. Tumor immune escape mediated by indoleamine 2,3-dioxygenase.
Zamanakou M; Germenis AE; Karanikas V
Immunol Lett; 2007 Aug; 111(2):69-75. PubMed ID: 17644189
[TBL] [Abstract][Full Text] [Related]
23. Indoleamine 2,3-dioxygenase promotes peritoneal metastasis of ovarian cancer by inducing an immunosuppressive environment.
Tanizaki Y; Kobayashi A; Toujima S; Shiro M; Mizoguchi M; Mabuchi Y; Yagi S; Minami S; Takikawa O; Ino K
Cancer Sci; 2014 Aug; 105(8):966-73. PubMed ID: 24826982
[TBL] [Abstract][Full Text] [Related]
24. Computational study on new natural compound inhibitors of indoleamine 2,3-dioxygenase 1.
Jiang S; Li H; Piao L; Jin Z; Liu J; Chen S; Liu LL; Shao Y; Zhong S; Wu B; Li W; Ren J; Zhang Y; Wang H; Jin R
Aging (Albany NY); 2020 Jun; 12(12):11349-11363. PubMed ID: 32568737
[TBL] [Abstract][Full Text] [Related]
25. Kynurenine pathway enzymes in dendritic cells initiate tolerogenesis in the absence of functional IDO.
Belladonna ML; Grohmann U; Guidetti P; Volpi C; Bianchi R; Fioretti MC; Schwarcz R; Fallarino F; Puccetti P
J Immunol; 2006 Jul; 177(1):130-7. PubMed ID: 16785507
[TBL] [Abstract][Full Text] [Related]
26. Astragaloside IV inhibits progression of lung cancer by mediating immune function of Tregs and CTLs by interfering with IDO.
Zhang A; Zheng Y; Que Z; Zhang L; Lin S; Le V; Liu J; Tian J
J Cancer Res Clin Oncol; 2014 Nov; 140(11):1883-90. PubMed ID: 24980548
[TBL] [Abstract][Full Text] [Related]
27. Synergistic antitumor effect with indoleamine 2,3-dioxygenase inhibition and temozolomide in a murine glioma model.
Hanihara M; Kawataki T; Oh-Oka K; Mitsuka K; Nakao A; Kinouchi H
J Neurosurg; 2016 Jun; 124(6):1594-601. PubMed ID: 26636389
[TBL] [Abstract][Full Text] [Related]
28. A novel immunohistochemical score to predict early mortality in acute myeloid leukemia patients based on indoleamine 2,3 dioxygenase expression.
Mangaonkar A; Mondal AK; Fulzule S; Pundkar C; Park EJ; Jillella A; Kota V; Xu H; Savage NM; Shi H; Munn D; Kolhe R
Sci Rep; 2017 Oct; 7(1):12892. PubMed ID: 29038460
[TBL] [Abstract][Full Text] [Related]
29. Indoleamine-2,3 dioxygenase: a fate-changer of the tumor microenvironment.
Azimnasab-Sorkhabi P; Soltani-Asl M; Yoshinaga TT; Zaidan Dagli ML; Massoco CO; Kfoury Junior JR
Mol Biol Rep; 2023 Jul; 50(7):6133-6145. PubMed ID: 37217614
[TBL] [Abstract][Full Text] [Related]
30. Indoleamine 2, 3-Dioxygenase: A Professional Immunomodulator and Its Potential Functions in Immune Related Diseases.
Heidari F; Ramezani A; Erfani N; Razmkhah M
Int Rev Immunol; 2022; 41(3):346-363. PubMed ID: 33118843
[TBL] [Abstract][Full Text] [Related]
31. Indoleamine 2,3-dioxygenase expression in human cancers: clinical and immunologic perspectives.
Godin-Ethier J; Hanafi LA; Piccirillo CA; Lapointe R
Clin Cancer Res; 2011 Nov; 17(22):6985-91. PubMed ID: 22068654
[TBL] [Abstract][Full Text] [Related]
32. Is IDO a key enzyme bridging the gap between tumor escape and tolerance induction?
Löb S; Königsrainer A
Langenbecks Arch Surg; 2008 Nov; 393(6):995-1003. PubMed ID: 18064486
[TBL] [Abstract][Full Text] [Related]
33. Highlights at the gate of tryptophan catabolism: a review on the mechanisms of activation and regulation of indoleamine 2,3-dioxygenase (IDO), a novel target in cancer disease.
Macchiarulo A; Camaioni E; Nuti R; Pellicciari R
Amino Acids; 2009 Jul; 37(2):219-29. PubMed ID: 18612775
[TBL] [Abstract][Full Text] [Related]
34. Uveal melanoma expression of indoleamine 2,3-deoxygenase: establishment of an immune privileged environment by tryptophan depletion.
Chen PW; Mellon JK; Mayhew E; Wang S; He YG; Hogan N; Niederkorn JY
Exp Eye Res; 2007 Nov; 85(5):617-25. PubMed ID: 17870068
[TBL] [Abstract][Full Text] [Related]
35. CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition.
von Bergwelt-Baildon MS; Popov A; Saric T; Chemnitz J; Classen S; Stoffel MS; Fiore F; Roth U; Beyer M; Debey S; Wickenhauser C; Hanisch FG; Schultze JL
Blood; 2006 Jul; 108(1):228-37. PubMed ID: 16522817
[TBL] [Abstract][Full Text] [Related]
36. Interferon-gamma-triggered indoleamine 2,3-dioxygenase competence in human monocyte-derived dendritic cells induces regulatory activity in allogeneic T cells.
Jürgens B; Hainz U; Fuchs D; Felzmann T; Heitger A
Blood; 2009 Oct; 114(15):3235-43. PubMed ID: 19625705
[TBL] [Abstract][Full Text] [Related]
37. Cyclooxygenase-2 (COX-2) inhibition constrains indoleamine 2,3-dioxygenase 1 (IDO1) activity in acute myeloid leukaemia cells.
Iachininoto MG; Nuzzolo ER; Bonanno G; Mariotti A; Procoli A; Locatelli F; De Cristofaro R; Rutella S
Molecules; 2013 Aug; 18(9):10132-45. PubMed ID: 23973990
[TBL] [Abstract][Full Text] [Related]
38. Regulation of indoleamine 2,3-dioxygenase and tryptophanyl-tRNA-synthetase by CTLA-4-Fc in human CD4+ T cells.
Boasso A; Herbeuval JP; Hardy AW; Winkler C; Shearer GM
Blood; 2005 Feb; 105(4):1574-81. PubMed ID: 15466932
[TBL] [Abstract][Full Text] [Related]
39. Indoleamine 2,3-dioxygenase regulates T cell activity through Vav1/Rac pathway.
Li R; Li H; Sun Q; Liu L; Zhang C; Ren X
Mol Immunol; 2017 Jan; 81():102-107. PubMed ID: 27930920
[TBL] [Abstract][Full Text] [Related]
40. Indoleamine 2,3-dioxygenase and dendritic cell tolerogenicity.
Harden JL; Egilmez NK
Immunol Invest; 2012; 41(6-7):738-64. PubMed ID: 23017144
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
